Public Health Scotland is responsible for the collection of information on Scottish residents when they are diagnosed with malignant (and some benign) tumours.

MDW Discover  > Scottish Cancer Registry (SMR06) @ 79

MDW Discover

Browse All

London SDE

West Midlands SDE

Kent, Medway & Sussex SDE

MDW - Discover

https://publichealthscotland.scot/services/data-research-and-innovation-services/electronic-data-research-and-innovation-service-edris/overview/what-is-edris/

https://www.researchdata.scot/media/gz1lpmk2/scottish-cancer-registry-smr06-variables.pdf

The registry began in 1958 collecting personal, demographic and diagnosis information (such as site, histology, behaviour, histological confirmation and hospital of diagnosis) from cancer patients. In 1997, a new electronic cancer recording system was launched and at this point the registry was extended to include extra information on tumour stage (for breast, cervical and colorectal cancer), tumour grade and treatment information. A wide variety of geographical data is also included in the dataset including Scottish Index of Multiple Deprivation and Carstairs measures, census output area, NHS Board, Electoral Ward and Parliamentary constituency.

HDR UK

National Services Scotland

Date of first Hormone Therapy DD-MMM-YYYY (if applicable)

Date of First 
Hormone Therapy

INITIAL TREATMENT

Institution code/practice code of Hospital/GP practice initiating Hormone Therapy (if applicable)

Hospital/GP 
Practice of First 
Hormone 
Therapy

Institution code/practice code of Hospital/GP practice where a surgical treatment was first carried out (if applicable)

Hospital/GP 
Practice of First Radical Surgery

Institution code/practice code of Hospital/GP practice of first Chemotherapy (if applicable)

Hospital/GP 
Practice of First Chemotherapy

Indicates if patient has had Hormone treatment. Hormone therapy is the use of hormones to treat cancer.  Hormones are 'chemical messengers' released by the organs and dispersed by the blood to produce effects on target organs e.g. oestrogens. Most likely to apply to Breast, Prostate, Endometrial (uterus) and to a lesser extent, hypernephroma of kidney. Options: 
 
Code 	Description 
0 	No 
1 	Yes 
7 	Planned 
	9 	 	Not Known 
This field is collected for all registrations with a Scottish incidence date from 1.1.1997.

Treated with hormone therapy

Institution code of Hospital where Radiotherapy was first carried out (if applicable)

Hospital/GP 
Practice of First Radiotherapy

Other Therapy. Options:  
Code 	Description 
0 	No 
1 	Yes 
7 	Planned 
	9 	 	Not Known 
This field is collected for all registrations with a Scottish incidence date from 1.1.1997.

Treated with other therapy

Indicates if patient has been treated with radiotherapy. Radiotherapy is either external beam, or the radioactive source can be introduced directly into the patient’s body. Radiotherapy may be used for: curative treatment e.g. early seminomas, palliative treatment to contain the tumour & control symptoms e.g. metastatic breast cancer, in combination with other curative treatments e.g. for tumours of the cervix, and to sites other than the primary or metastases e.g. organ ablation or prophylaxis.  
Options:  
Code 	Description 
0 	No 
1 	Yes 
7 	Planned 
	9 	 	Not Known 
 
This field is collected for all registrations with a Scottish incidence date from 1.1.1997.

Treated with Radiotherapy

Hospital/GP 
Practice of First 
(Palliative) Surgery

Type of radiotherapy administered collected from 01.01.2016. Options: 
Code 	Description 
1 	Brachytherapy 
2 	External beam/Teletherapy 
3 	Proton beam therapy 
	4 	 	Radioisotope therapy 
9 	Not Known

Type of radiotherapy

Hospital/GP Practice  
of First 
Biological/Immun otherapy

Formerly Treatment Protocol Used This indicates whether the patient has been recruited into a specific clinical trial. Only use the Not Known option if you feel you do not have an adequate set of medical records on which to base your assessment.  Options: 
Code 	Description 
0 	No 
1 	Yes 
9 	Not Known 
This field is collected for all registrations with a Scottish incidence date from 1.1.1997.

Entered into 
Clinical Trial

Date of first radical surgical treatment DD-MMM-YYYY (if applicable)

Date of First 
(Palliative) Surgery

Date of First Radical Surgery

Date of first Chemotherapy DD-MMM-YYYY (if applicable)

Date of First Chemotherapy

Palliative Surgery -there are 4 options for this treatment field:  
Code 	Description 
0 	No -  no palliative surgery  
1 	Yes – to relieve the effects of the tumour but not to remove the tumour e.g. stent/shunt 
7 	Planned – palliative surgery is planned at a later date 
	9 	 	Not Known - there are no indications of any past or planned palliative surgical procedures relating to the neoplasm concerned 
 
This field is collected for all registrations with a Scottish incidence date from 1.1.2016

Treated with 
Palliative Surgery

Date of First 
Biological/Immun otherapy

Referred to a Clinical Oncologist (Radiotherapist) or Medical Oncologist.  Options: 
Code 	Description 
0 	No 
1 	Yes 
7 	Planned to refer 
	9 	 	Not Known 
This field is collected for all registrations with a Scottish incidence date from 1.1.1997.

Referred to Oncologist

Hospital of diagnosis denotes the location (institution) code of the hospital in which the diagnosis was first made. This may also be a GP surgery code if an initial biopsy was taken by a GP. 
This field is collected for all registrations with a Scottish incidence date from 1.1.1997. For registrations with a Scottish incidence date up to 31.12.1996, see Old Hosp Code field on Stats screen.

Hospital / GP of diagnosis

Indicates the type of Other Therapy treatment carried out. Options: 
Code 	Description 
1 	Anagrelide 
2 	Anti-Helicobacter/H.pylori  treatment/eradication therapy  
3 	Bisphosphonate 
	4 	 	Botox injection 
5 	Corticosteroids 
6 	Dopamine agonist therapy 
7 	Helmet/Electric Helmet 
8 	Hyperbaric oxygen therapy 
9 	Supportive Care/Best Supportive Care 
10 	Venesection   
11 	No longer in use (Watchful Wait - See option 13)  
12 	Embolisation 
13 	Active Surveillance/Watchful Wait 
14 	Not Known 
15 	Photopheresis  
 
This field was previously text only and was collected for all registrations with a Scottish incidence date from 1.1.1997. 
This field changed to a dropdown option for registrations from 1.1.2016

Type of other therapy

Institution code/practice code of Hospital/GP surgery where Other Therapy was first carried out (if applicable)

Hospital/GP 
Practice of Other Therapy

This is the reason why no treatment has taken place. It applies to all registerable cancers with a Scottish incidence date from 1.1.2017. This is only to be completed if no treatment has taken place.  
 
 
Options: 
0 	Died before treatment was given 
1 	Refused treatment 
2 	Asymptomatic 
3 	Death Certificate only 
4 	Post-mortem only 
5 	Unfit to treat: significant co-morbidity and/or advanced cancer 
6 	No record of treatment 
7 	Other 
8 	Unknown primary site 
9 	No active treatment available 
10 	Not Known

No Treatment Reason

Radiotherapy treatment to Metastases. Options:  
Code 	Description 
0 	No 
1 	Yes 
	9 	 	Not Known

Radiotherapy to 
Metastases

Radiotherapy treatment to Other (such as organ ablation or prophylaxis). Options:  
Code 	Description 
0 	No 
1 	Yes 
	9 	 	Not Known

Radiotherapy Other

Radiotherapy treatment to Primary site. Options: 
Code 	Description 
0 	No 
1 	Yes 
	9 	 	Not Known

Radiotherapy to 
Primary

Indicates if patient has had Systemic chemotherapy treatment. 
Chemotherapy literally means treatment with drugs but is conventionally used to describe the use of chemical agents to treat cancer. These agents may be used alone, or in conjunction with surgery and/or radiotherapy. Options:  
Code 	Description 
0 	No 
1 	Yes 
7 	Planned 
	9 	 	Not Known 
 
This field is collected for all registrations with a Scottish incidence date from 1.1.1997.

Treated with Chemotherapy

Intent is most likely to be curative in early stage of disease e.g. microinvasive, or non invasive, in situ disease, T1 or T2  N0  M0 , node negative breast cancer, Dukes’ A colorectal cancer, FIGO I cervical cancer. Intent unlikely to be curative in advanced disease e.g. M1 breast cancer, Dukes’ D, FIGO IV.  
 
Options:  
Code 	Description 
1 	Curative intent 
2 	Non-curative intent (Palliative) 
9 	Not Known 
 
This field is collected for all registrations with a Scottish incidence date from 1.1.1997.

Therapy 
Objectives

Date of first Other Therapy DD-MMM-YYYY (if applicable)

Date of First Other Therapy

Surgery -there are 4 options for this treatment field:  
Code 	Description 
0 	No -  no surgery OR exploratory surgery only with or without diagnostic biopsy [e.g. diagnostic laparotomy with or without incisional biopsy (‘open and close’), needle biopsy, and diagnostic endoscopy with or without incisional biopsy 
1 	Yes - partial or total resection of primary and/or metastases (including endoscopic resection or biopsy where there is intent to remove all or bulk of macroscopic neoplastic tissue, e.g., excision biopsy or cone biopsy). Surgery should also include palliative procedures e.g. to bypass obstructive lesions or surgical procedures intended to manipulate hormone levels e.g. by the removal of ovaries or testicles 
7 	Planned - surgery is planned at a later date 
	9 	 	Not Known - there are no indications of any past or planned surgical procedures relating to the neoplasm concerned 
 
This field is collected for all registrations with a Scottish incidence date from 1.1.1997 - 31.12.2015 incidence 
.

Treated with Surgery

Radical Surgery -there are 4 options for this treatment field:  
Code 	Description 
0 	No -  no radical surgery  
1 	Yes – removal, part removal or destruction of the primary tumour e.g. excision, resection or laser treatment. It may also include resection of metastasis 
7 	Planned – radical surgery is planned at a later date 
	9 	 	Not Known - there are no indications of any past or planned radical surgical procedures relating to the neoplasm concerned 
 
This field is collected for all registrations with a Scottish incidence date from 1.1.2016 
.

Treated with 
Radical Surgery

Date of first Radiotherapy treatment DD-MMM-YYYY (if applicable)

Date of First Radiotherapy

Indicates if patient has had Biological/Immunotherapy. Biological therapies are treatments that act on processes in cells. They may: stop cancer cells from dividing and growing; seek out cancer cells and kill them; encourage the immune system to attack cancer cells. There are many different types of biological therapies including immunotherapy. Options: 
 
Code 	Description 
0 	No 
1 	Yes 
7 	Planned 
	9 	 	Not Known 
 
This field is collected for all registrations with a Scottish incidence date from 1.1.1997

Treated with Biological/Immun otherapy

FIGO Stage will be collected for malignant tumours of the ovary (ICD10 C56*) with a Scottish incidence date from 1.1.2005 onwards. 
FIGO Stage classification change from 1.1.2014  
See also FIGO stage before surgery. Options are the same for before or after surgery

FIGO StageAfter Surgery (Ovary only)

STAGE DETAILS

FIGO Stage will be collected for malignant tumours of the Peritoneum (ICD10 C48*) with an incidence date from 1.1.2005 onwards. 
FIGO Stage classification change from 1.1.2014  
See also FIGO stage after surgery. Options are the same for before or after surgery 
 
 
Code 	Description 
1 	Tumour confined to the Ovaries (one or both) or fallopian tube(s)  
1a 	Tumour limited to 1 ovary, capsule intact, no tumour on ovarian or fallopian tube surface, negative washings 
1b 	Tumour involves both ovaries or fallopian tubes, capsule intact, no tumour on surface, negative washings  
1c 	Tumour involves 1 or both ovaries or fallopian tubes 
1c1 	Tumour involves 1 or both ovaries or fallopian tubes with surgical spill 
1c2 	Tumour involves 1 or both ovaries or fallopian tubes with ovarian capsule rupture prior to surgery or tumour on ovarian or tube surface 
1c3 	Tumour involves 1 or both ovaries or fallopian tubes with malignant cells in ascites or peritoneal fluid 
2 	Tumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below the pelvic brim) or primary peritoneal cancer in the pelvis 
2a 	Extension and/or implant on uterus and/or Fallopian tubes or ovaries 
2b 	Extension to other pelvic intraperitoneal tissues including bowel within the pelvis 
3 	Tumour involves 1 or both ovaries or fallopian tubes or primary peritoneal carcinoma with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes 
3a 	Positive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis) 
3a1 	Positive retroperitoneal lymph nodes only 
3a1i 	Positive retroperitoneal lymph node metastases ? 10 mm 
3a1ii 	Positive retroperitoneal lymph node metastases Metastasis > 10 mm 
	3a2 	 	Microscopic, extrapelvic (above the brim) peritoneal involvement ± positive retroperitoneal lymph nodes including bowel movement 
3b 	Macroscopic, extrapelvic, peritoneal metastasis ? 2 cm ± positive  retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. 
3c 	Macroscopic, extrapelvic, peritoneal metastasis >2 cm ± positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen but not parenchymal involvement 
4 	Distant metastasis excluding peritoneal metastasis 
4a 	Pleural effusion with positive cytology 
4b 	Hepatic and/or splenic parenchymal metastasis, metastasis to extra - abdominal organs (including inguinal lymph nodes and lymph nodes outside  of the abdominal cavity) 
9 	Not known

Before Surgery (Peritoneum)

FIGO Stage indicates the extent of spread of the invasive primary tumour for cervix at diagnosis in terms of the pathological and/or clinical findings for Socrates. FIGO stage has been collected for malignant tumours of the cervix (ICD10 C53*) with a Scottish incidence  date from 1.1.1997 onwards.  
This is a new field to record stage before surgery if possible, and will be collected for all malignant tumours of the cervix (C53*) from 1.1.2005. 
See also FIGO stage after surgery. Options are the same for before or after surgery. 
 
Options for cervix:  
Code 	Description 
1 	Tumour strictly confined to cervix (extension to the corpus uteri should be disregarded) 
2 	Tumour extends beyond the cervix/uterus but not as far as pelvic wall or lower third of the vagina 
3 	Tumour extends to the pelvic wall or lower third of the vagina (includes all cases with hydronephrosis or non-functioning kidney or both) 
4 	Tumour has invaded or spread beyond the true pelvis, bone, or has clinically involved the mucosa (lining) of the bladder or rectum (bullous oedema as such does not permit a case to be allotted to stage IV) 
9 	Not Known 
FIGO Stage classification change and from 1.1.2014. See also FIGO stage after surgery. Options are the same for before or after surgery. Options: 
Code 	Description 
1 	The carcinoma is strictly confined to the cervix (extension to the corpus would be disregarded). 
1a 	Invasive carcinoma which can be diagnosed only by microscopy. All macroscopically visible lesions - even with superficial invasion - are allotted to Stage Ib carcinomas. Invasion is limited to a measured stromal invasion with a maximal depth of 5.0 mm and horizontal extension of not > 7.0 mm. Depth of invasion should not be > 5.0 mm taken from the base of the epithelium of the original tissue - superficial or glandular. The involvement of vascular spaces should not change the stage allotment. 
1a1 	Measured stromal invasion of not > 3.0 mm in depth and extension of not > 7.0 mm. 
1a2 	Measured stromal invasion of > 3.0 mm and not > 5.0 mm with an extension of not > 7.0 mm. 
1b 	Clinically visible lesions limited to the cervix uteri or preclinical cancers greater than Stage IA. 
1b1 	Clinically visible lesions not > 4.0 cm. 
1b2 	Clinically visible lesions > 4.0 cm. 
2 	Cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina. 
2a 	No obvious parametrial involvement. 
2a1 	Clinically visible lesion <=4.0 cm in greatest dimension 
2a2 	Clinically visible lesion >4.0 cm in greatest dimension 
2b 	Obvious parametrial involvement. 
3 	The carcinoma has extended to the pelvic wall. On rectal examination, there is no cancer-free space between the tumour and the pelvic wall. The tumour involves the lower-third of the vagina. All cases with hydronephrosis or non-functioning kidney are included, unless they are known to be due to other causes. 
3a 	Tumour involves lower-third of the vagina, with no extension to the pelvic wall. 
3b 	Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney 
4 	The carcinoma has extended beyond the true pelvis, or has involved (biopsy-proven) the mucosa of the bladder or rectum. A bullous oedema, as such, does not permit a case to be allotted to Stage IV. 
4a 	Spread of the growth to adjacent organs. 
4b 	Spread to distant organs. 
9 	Not known

FIGO Stage – Before Surgery (Cervix only)

FIGO Stage will be collected for malignant tumours of the Corpus Uteri (ICD10 C54*) with a Scottish incidence date from 1.1.2005 onwards. 
FIGO Stage classification change from 1.1.2014  
See also FIGO stage before surgery. Options are the same for before or after surgery

FIGO StageAfter Surgery (Corpus Uteri only)

Stage (Colorectal) indicates the extent of spread of the invasive tumour at diagnosis in terms of the pathological and/or clinical findings for Socrates. Extent of Primary tumour for Colorectal cancer - 
Dukes’ staging is primarily based on histological findings.  Dukes’ Staging Classification Options: 
 
Code 	Description 
A 	Tumour limited to muscularis propria (muscle coat), regional lymph nodes negative 
B 	Tumour invades through muscularis propria into serosa/subserosa or through peritoneum but regional lymph nodes negative 
C1 	Regional lymph nodes positive but apical node negative 
C2 	Regional lymph nodes positive, apical lymph node positive 
D 	Distant metastases (e.g. liver) 
9 	Not Known 
Note: Dukes’ stage D was not included in the original Dukes’ classification 
Note:  Regional lymph nodes are the pericolic and perirectal and those located along the ileocolic, right colic, middle colic, left colic, inferior mesenteric and superior rectal (haemorrhoidal) arteries 
This field is collected for all registrations with a Scottish incidence date from 1.1.1997 onwards for all malignant colorectal (ICD10 C18 – C20) and anal (ICD10 C21) tumours.

Dukes’ Stage (Colorectal only)

FIGO Stage will be collected for malignant tumours of the Fallopian Tube (ICD10 C57*) with a Scottish incidence date from 1.1.2005 onwards. 
FIGO Stage classification change from 1.1.2014  
See also FIGO stage after surgery. Options are the same for before or after surgery 
 
 
	Code 	Description 
	1 	Tumour confined to the Ovaries (one or both) or fallopian tube(s)  
	1a 	Tumour limited to 1 ovary, capsule intact, no tumour on ovarian or fallopian tube surface, negative washings 
	1b 	Tumour involves both ovaries or fallopian tubes, capsule intact, no tumour on surface, negative washings  
	1c 	Tumour involves 1 or both ovaries or fallopian tubes 
	1c1 	Tumour involves 1 or both ovaries or fallopian tubes with surgical spill 
	1c2 	Tumour involves 1 or both ovaries or fallopian tubes with ovarian capsule rupture prior to surgery or tumour on ovarian or tube surface 
	1c3 	Tumour involves 1 or both ovaries or fallopian tubes with malignant cells in ascites or peritoneal fluid 
	2 	Tumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below the pelvic brim) or primary peritoneal cancer in the pelvis 
	2a 	Extension and/or implant on uterus and/or Fallopian tubes or ovaries 
	2b 	Extension to other pelvic intraperitoneal tissues including bowel within the pelvis 
	3 	Tumour involves 1 or both ovaries or fallopian tubes or primary peritoneal carcinoma with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes 
	3a 	Positive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis) 
	3a1 	Positive retroperitoneal lymph nodes only 
	3a1i 	Positive retroperitoneal lymph node metastases ? 10 mm 
	3a1ii 	Positive retroperitoneal lymph node metastases Metastasis > 10 mm 
		3a2 	 	Microscopic, extrapelvic (above the brim) peritoneal involvement ± positive retroperitoneal lymph nodes including bowel movement 
	3b 	Macroscopic, extrapelvic, peritoneal metastasis ? 2 cm ± positive  retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. 
	3c 	Macroscopic, extrapelvic, peritoneal metastasis >2 cm ± positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen but not parenchymal involvement 
	4 	Distant metastasis excluding peritoneal metastasis 
	4a 	Pleural effusion with positive cytology 
4b 	Hepatic and/or splenic parenchymal metastasis, metastasis to extra - abdominal organs (including inguinal lymph nodes and lymph nodes outside  of the abdominal cavity) 
9 	Not known

FIGO Stage-Before Surgery (Fallopian Tube)

Options: 
Code 	Description 
1 	Localised 
2 	Regional spread    
3 	Distant metastasis   
4 	Not Known 
 
This field will be collected for all malignant lung tumours (C34*) registered with a Scottish incidence date from 1.1.2005 to 31.12.2012

Clinical extent of disease (Lung only)

FIGO Stage will be collected for malignant tumours of the Fallopian Tube (ICD10 C57*) with a Scottish incidence date from 1.1.2005 onwards. 
FIGO Stage classification change from 1.1.2014  
See also FIGO stage before surgery. Options are the same for before or after surgery

FIGO StageAfter Surgery (Fallopian Tube)

FIGO Stage indicates the extent of spread of the invasive primary tumour for cervix at diagnosis in terms of the pathological and/or clinical findings for Socrates. 
Previously this field was known as FIGO Stage, and was collected for all malignant tumours of the cervix (ICD10 C53*) from 1.1.1997 onwards. All tumours recorded with a FIGO stage from 1.1.1997 to 31.12.2004 will exist on the SOCRATES database with a FIGO stage in the After Surgery field. 
FIGO Stage classification change from 1.1.2014  
See also FIGO stage before surgery. Options are the same for before or after surgery

FIGO StageAfter Surgery (Cervix only)

FIGO Stage indicates the extent of spread of the invasive primary tumour for Corpus Uteri (C54#) at diagnosis in terms of the pathological and/or clinical findings for Socrates. 
FIGO Stage classification change from 1.1.2014 to include Corpus Uteri 
See also FIGO stage after surgery. Options are the same for before or after surgery. 
 
Code 	Description 
1 	Tumour contained to corpus uteri 
1a 	No or less than half myometrial invasion 
1b 	Invasion equal to or more than half of the myometrium 
2 	Tumour invades the cervical stroma but does not extend beyond the uterus 
3 	Local and/or regional spread of tumour 
3a 	Tumour invades the serosa of the corpus uteri and/or adnexas 
3b 	Vaginal and/or parametrial involvement 
3c 	Metastases to pelvis and/or para-aortic lymph nodes 
3c1 	Positive pelvic nodes 
3c2 	Positive para-aortic lymph nodes with or without positive pelvic lymph nodes 
4 	Tumour invades into bladder and/or bowel mucosa and/or distant metastasis 
4a 	Tumour invasion bladder and/or bowel 
4b 	Distant metastases including intra-abdominal and/or inguinal lymph nodes 
9 	Not known

FIGO Stage-
Before Surgery (Corpus Uteri only)

This staging group indicates the extent of disease progression of invasive testicular tumours.  (ICD10 C62*) with an incident date from 1.1.2015.
 
Options are: 
Code 
I 
IA 
IB 
II 
IIA 
IIB 
IIC 
III 
IIIA 
IIIB 
IIIC 
IS 
NK

Staging Group Testicular

FIGO Stage will be collected for malignant tumours of the ovary (ICD10 C56*) with a Scottish incidence date from 1.1.2005 onwards. As with cervix, this is a new field. 
See also FIGO stage after surgery. Options are the same for before or after surgery. 
 
Code 	Description 
1 	Tumour confined to the Ovaries (one or both) or fallopian tube(s)  
1a 	Tumour limited to 1 ovary, capsule intact, no tumour on ovarian or fallopian tube surface, negative washings  
1b 	Tumour involves both ovaries or fallopian tubes, capsule intact, no tumour on surface, negative washings  
1c 	Tumour involves 1 or both ovaries or fallopian tubes  
 
1C1 	Tumour involves 1 or both ovaries or fallopian tubes with surgical spill  
1C2 	Tumour involves 1 or both ovaries or fallopian tubes with ovarian capsule rupture prior to surgery or tumour on ovarian or tube surface  
1C3 	Tumour involves 1 or both ovaries or fallopian tubes with malignant cells in ascites or peritone 
Tumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below the pelvic brim) or primary peritoneal cancer in the pelvis  al fluid  
2 	Tumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below the pelvic brim) or primary peritoneal cancer in the pelvis  
2a 	Extension and/or implant on uterus and/or Fallopian tubes or ovaries  
2b 	Extension to other pelvic intraperitoneal tissues including bowel within the pelvis  
3 	Tumour involves 1 or both ovaries or fallopian tubes or primary peritoneal carcinoma with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes  
3A 	Positive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis)  
3A1 	Positive retroperitoneal lymph nodes only  
3A1i 	Positive retroperitoneal lymph node metastases ? 10 mm  
3A1ii 	Positive retroperitoneal lymph node metastases Metastasis > 10 mm  
3A2 	Microscopic, extrapelvic (above the brim) peritoneal involvement ± positive retroperitoneal lymph nodes including bowel movement  
3B 	Macroscopic, extrapelvic, peritoneal metastasis ? 2 cm ± positive  retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen.  
3C 	Macroscopic, extrapelvic, peritoneal metastasis >2 cm ± positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen but not parenchymal involvement  
4 	Distant metastasis excluding peritoneal metastasis 
4A 	Pleural effusion with positive cytology  
4B 	Hepatic and/or splenic parenchymal metastasis, metastasis to extra - abdominal organs (including inguinal lymph nodes and lymph nodes outside  of the abdominal cavity)  
9 	Not Known 
 
FIGO Stage classification change and from 1.1.2014 the options are: 
See also FIGO stage after surgery. Options are the same for before or after surgery. 
 
 
	Code 	Description 
1 	Tumour confined to the Ovaries (one or both) or fallopian tube(s)  
1a 	Tumour limited to 1 ovary, capsule intact, no tumour on ovarian or fallopian tube surface, negative washings 
1b 	Tumour involves both ovaries or fallopian tubes, capsule intact, no tumour on surface, negative washings  
1c 	Tumour involves 1 or both ovaries or fallopian tubes with the following features: 
1c1 	Tumour involves 1 or both ovaries or fallopian tubes with surgical spill 
1c2 	Tumour involves 1 or both ovaries or fallopian tubes with ovarian capsule rupture prior to surgery or tumour on ovarian or tube surface 
1c3 	Tumour involves 1 or both ovaries or fallopian tubes with malignant cells in ascites or peritoneal fluid 
2 	Tumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below the pelvic brim) or primary peritoneal cancer in the pelvis 
2a 	Extension and/or implant on uterus and/or Fallopian tubes or ovaries 
2b 	Extension to other pelvic intraperitoneal tissues including bowel within the pelvis 
3 	Tumour involves 1 or both ovaries or fallopian tubes or primary peritoneal carcinoma with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes 
3a 	Positive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis) 
3a1 	Positive retroperitoneal lymph nodes only 
3a1i 	Positive retroperitoneal lymph node metastases ? 10 mm 
3a1ii 	Positive retroperitoneal lymph node metastases Metastasis > 10 mm 
	3a2 	 	Microscopic, extrapelvic (above the brim) peritoneal involvement ± positive retroperitoneal lymph nodes including bowel movement 
3b 	Macroscopic, extrapelvic, peritoneal metastasis ? 2 cm ± positive  retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. 
3c 	Macroscopic, extrapelvic, peritoneal metastasis >2 cm ± positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen but not parenchymal involvement 
4 	Distant metastasis excluding peritoneal metastasis 
4a 	Pleural effusion with positive cytology 
4b 	Hepatic and/or splenic parenchymal metastasis, metastasis to extra - abdominal organs (including inguinal lymph nodes and lymph nodes outside  of the abdominal cavity) 
9 	Not known

FIGO Stage – Before Surgery (Ovary only)

Please refer to staging document 
AJCC – American Joint Committee on Cancer indicates the extent of disease progression of invasive melanoma tumours. 
AJCC is collected for malignant melanomas of the skin (ICD10 C43*) with an incident date from 
1.1.2015 
Options for AJCC version 7 are: 
Code 
IA 
IB 
IIA 
IIB 
IIC 
III 
IIIA 
IIIB 
IIIC 
IV 
X 
 
From 01.01.2018 the following options apply for AJCC version 8: 
 
 	Code 
	IA 
	IB 
	IIA 
	IIB 
	IIC 
	III 
	IIIA 
	IIIB 
	IIIC 
	IIID 
	IV 
	X

TNM AJCC (Melanoma)

Tick box to indicate that a registration has been considered to be an independent primary tumour, regardless of the existence of other registrations with a similar diagnosis.

Independent Primary Tumour

SYSTEM ADMINISTRATION DATA (Person & tumour level)

SYSTEM ADMINISTRATION DATA

Indicates if the record is a provisional registration, a validated / confirmed registration, or a previously deleted registration

Confirmed,Provisional or Deleted

If transferred to another hospital batch this field will indicate where the provisional registration was last transferred from

Previous Hospital

ICDO(3) - International Classification of Diseases for Oncology (3rd revision). Tumour type indicates the morphology (histology) of the tumour and comprises the first four digits of the ICDO(3) morphology code and a fifth digit which denotes behavior. This is recorded for haematological transformations  which have occurred since 01.01.2013

Transformation ICDO3

‘Berg’ grouping for similar morphological families

Berg Morphology

Derived from Quality Checks. Indicates date and description of check. Options: 
Code 	Description 
10 	Non-specific morphology 
11 	18QA 
12 	Under 25 no treatment 
13 	NK Staging 
14 	Scheduled QA

Checks

Hospital code is allocated by the system according to the data source where it is presumed the medical records with the most information on the patient will be available. Once this code has been allocated the CRO(s) who work with that institution or area will be able see these provisional records in their batch. This code will usually be associated with the provisional notification before registration, and may not correspond to the registered hospital of diagnosis & Case Ref. no.

Hospital  Code

Indicates that a particular quality check has been completed for a particular record. There are a growing number of options due to the development of a more comprehensive quality assurance programme in Cancer Registration.

Quality Checks

The initial date the provisional registration was inserted into the hospital batch for the Cancer Information

Date into Batch

Officer (CIO) to work with SOCRATES Grouping for similar tumour site families

Subcluster Code

Indicates that a haematological transformation has occurred recorded for Scottish incidence year 2013 onwards

Transformation Date

Last Updated Date

Code denoting the last Cancer Information Officer (CIO) who made an amendment to the registration

Last Updated By

Latest comment to be added regarding the tumour. There is a List Notes button available to view previous notes.

Latest Note

Date provisional registration was last transferred

Transfer Date

ICD10 – International Classification of Diseases (10th revision) recorded for haematological transformations which have occurred since 01.01.2013

Transformation ICD10

Secondary Cause of death x 3 indicates other causes of death. Obtained through NRS linkage and are coded ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Information Officer (CIO) cannot fill this field in. 
From 01.01.2013 Cause of death was increased to x8

Cause of Death 3

PERSON RECORD

Patient’s full date of birth only. The date of birth at person & tumour level may not be the same. Therefore this field is used for the DOB confirmed to be correct. i.e. the latest used or most commonly used if it is a valid date. The main format inclusive of century is DD-MMM-YYYY e.g. 9th Feb 42 is 09-FEB-1942 this is then saved onto the main oracle table as YYYYMMDD 19420242.

Date of Birth  (P_DATE_OF_BIRTH)

This field is collected for all registrations with a Scottish incidence date from 1.1.1997  These are used by NHS Scotland organisations for local and national return purposes. 
It describes the patient’s perception of their Ethnic Group. For patients with more than one registration, the Ethnic Group will be updated to reflect the most recent date option. 
Originally these were based on the UK Dept. Of Health recommendations (Part of COPPISH SMR patient ID section)   
-  From 1.1.1997 to 30.9.2005 Scottish incidence Ethnic Group 1 options:  
 
Ethnic Group 1 
Code 	Description 
00 	White 
01 	Black Caribbean 
02 	Black African 
03 	Black Other 
04 	Indian 
05 	Pakistani 
06 	Bangladeshi 
07 	Chinese 
08 	Other Ethnic Group 
09 	Not Known 
10 	Refused 
The following codes were created to reflect the Scottish Census 2001 categories and were used for a short time in conjunction with the old codes. 
-	From 1.10.2005 to 31.3.2006 Scottish incidence. Ethnic Group 1 options OR Ethnic Group 2 options:  
 
Ethnic Group 2 
Code 	Description 
1A 	White-Scottish 
1B 	White-other British 
1C 	White-Irish 
1D 	Any other white background 
2A 	Any mixed background 
3A 	Indian 
3B 	Pakistani 
3C 	Bangladeshi 
3D 	Chinese 
3E 	Any other Asian background 
4A 	Caribbean 
4B 	African 
4C 	Any other black background 
5A 	Any other ethnic background 
97 	Refused/not provided by the patient 
99 	Not known 
 
-	From 1.4.2006 to 31.3.2010 Scottish incidence Ethnic Group 2 options only 
 
-	From 1.4.2010 to 30.9.2010 Scottish incidence  Ethnic Group 2 options OR Ethnic Group 3 options:  
Ethnic Group 3 
Code 	Description 
1A 	White-Scottish 
1E 	White-English 
1F 	White - Welsh 
1G 	White-Northern Irish 
1H 	White British 
1J 	White-Irish 
1K 	Gypsy/Traveler 
IL 	Polish 
1Z 	Any other white ethnic background 
2A 	Any mixed or multiple ethnic groups 
3F 	Pakistani, Pakistani Scottish or Pakistani British 
3G 	Indian, Indian Scottish or Indian British 
3H 	Bangladeshi, Bangladeshi Scottish or Bangladeshi British 
3J 	Chinese, Chinese Scottish or Chinese British 
3Z 	Other Asian 
4D 	African, African Scottish or African British 
4E 	Caribbean, Caribbean Scottish or Caribbean British 
4F 	Black, Black Scottish or Black British 
4Z 	Other African, Caribbean or Black 
5B 	Arab 
5X 	Other Ethnic Group 
98 	Refused/not provided by the patient 
	99 	Not known 
 
 
-	From 1.10.2010 to 30.9.2011 Scottish incidence.  Ethnic Group 3 options only 
Further changes have been made following a review of ethnicity recording in the 2011 Scottish Census. 
 
-	From 1.10.2011 to 31.3.2012 Scottish incidence.  Ethnic Group 3 options OR Ethnic Group 4 options 
 
Ethnic Group 4 
Code 	Description 
1A 	White-Scottish 
1B 	White- Other British 
1C 	Irish 
1K 	Gypsy/Traveller 
IL 	Polish 
1Z 	Any other white ethnic background 
2A 	Any mixed or multiple ethnic groups 
3F 	Pakistani, Pakistani Scottish or Pakistani British 
3G 	Indian, Indian Scottish or Indian British 
3H 	Bangladeshi, Bangladeshi Scottish or Bangladeshi British 
3J 	Chinese, Chinese Scottish or Chinese British 
3Z 	Other Asian, Asian Scottish or Asian British 
4D 	African, African Scottish or African British 
4Y 	Other African 
5C 	Caribbean, Caribbean Scottish or Caribbean British 
5D 	Black, Black Scottish or Black British 
5B 	Arab 
5Y 	Other Caribbean or Black 
6A 	Arab, Arab Scottish or Arab British 
6Z 	Other Ethnic Group 
98 	Refused/not provided by the patient 
99 	Not known 
- From 1.4.2012 Scottish incidence.  Ethnic Group 4 options only

Ethnic Group

A unique number which will enable the unequivocal identification of individual cancer patients. It is a sequential number allocated by the computer system SOCRATES (For historical data it will result from person-based linkage). It uniquely identifies each person depending on person-based linkage and is subject to change if linkage is reviewed.

Person Identifier

Latest Surname from the last registration completed (if no previous registrations then name used for provisional notification).

Latest Surname

All surnames by which this person has been known. This includes maiden names, aliases or differences in spelling.

All Surnames

Living Status of Patient. Options:  
Code 	Description 
1 	Alive 
2 	Dead 
3 	Moved out of Scotland 
6 	Presumed deceased 
9 	Not Known

Vital Status

Secondary Cause of death x 3 indicates other causes of death. Obtained through NRS linkage and are coded ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Information Officer (CIO) cannot fill this field in. 
From 01.01.2013 Cause of death was increased to x9

Cause of Death 4

Latest forename from the last registration completed.

Latest Forename

Date of leaving Scotland (or UK) may be entered by the Cancer Information Officer (CIO) or obtained through nationwide NHSCR linkages.

Embarkation Date

Secondary Cause of death x 3 indicates other causes of death. Obtained through NRS linkage and are coded ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Information Officer (CIO) cannot fill this field in. 
From 01.01.2013 Cause of death was increased to x12

Cause of Death 7

Pre-CHI is a tick box which can be used to break/remove bad UPI linkages.

Pre-CHI

This should be ticked to indicate that a patient has died out with Scotland and we have been notified by another Cancer Registry. Death will not be notified through the NRS linkage. This field may explain discrepancy between SOCRATES and ISD warehouse data. This tick box was introduced in the redeveloped SOCRATES.

OOS (Out of Scotland)

Secondary Cause of death x 3 indicates other causes of death. Obtained through NRS linkage and are coded ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Information Officer (CIO) cannot fill this field in. 
From 01.01.2013 Cause of death was increased to x11

Cause of Death 6

Primary Cause of death. Obtained through NRS linkage and are be coded in ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Registry receives death notifications from various sources - NHSCR, CIO's directly view hospital systems, CHI, other cancer registries, genetic clinics and NRS.

Cause of Death 1

Secondary Cause of death x 3 indicates other causes of death. Obtained through NRS linkage and are coded ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Information Officer (CIO) cannot fill this field in. 
From 01.01.2013 Cause of death was increased to x10

Cause of Death 5

Not validated but used to record information on the person not provided elsewhere.

Person Comments

Sex (Gender) of the patient. The persons state of being Male or Female. For those who have under gone gender re-assignment there may be a mismatch recorded between sex and ICD10 code.   Options:
Code Description
0 Not Known (i.e. indeterminate sex, includes intersex)
1 Male
2 Female
9 Not Specified (includes not states by patient, or not recorded)

Sex (Gender)

A Unique Patient Identifier (UPI) was determined to be the CHI number which was most current at the time the indexes were linked ie. The record with the latest date of acceptance on a GP record.  10 digit number consists of 6-digit DOB (DDMMYY) followed by 4 check digits (9th digit denotes sex. 1,3,5,7 or 9 =male, 2,4,6,8 or 0 =female). This field is automatically populated by ascertaining the derived UPI by linking the CHI number held within the Registration Diagnosis screen directly to the CHI database. The Socrates system is also automatically CHI seeded during production run linkage.

Derived UPI (P_DERIVED_UPI)

Date of patient’s death may be entered by the Cancer Information Officer (CIO) or obtained through linkage to the National Records of Scotland (NRS). The Cancer Registry receives death notifications from various sources - NHSCR, CIO's directly view hospital systems, CHI, other cancer registries, genetic clinics and NRS. Format DD-MMM-YYYY.

Date of Death

Secondary Cause of death x 3 indicates other causes of death. Obtained through NRS linkage and are coded ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Information Officer (CIO) cannot fill this field in. 
From 01.01.2013 Cause of death was increased to x7

Cause of Death 2

Forenames

Source Data

Indicates the creation rule decision (NEW – new tumour, MP1 – different at sub cluster code etc)

Create Point

Surname

Incidence Date

Site code used for notifications before any conversions.

Unconverted Site 8

SOC link

Date Of Birth

Unique number generated for CDP (Cancer Data Processing) for all notifications.

Accession Number

Additional information from the Pathology text i.e. site of tumour/excision/substance

Type

Local Patient ID

Hospital code converted from text input if pathology data or 3 digit code if WGH radiotherapy data

Scottish Cancer Registry (SMR06)

Documentation

Coverage

Provenance

Temporal

Accessibility

Access

Usage

Format and Standards

Observations

Origin